# US 2012/0252847 A1 · Novel form of s-omeprazole

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0252847 A1
- Document ID: US20120252847A1
- Status: Published application
- Kind: A1
- Application number: 13/298,373
- Filed: 2011-11-17
- Published: 2012-10-04
- Earliest claimed: 1997-05-30
- Assignees: AstraZeneca AB
- Inventors: Hanna Cotton; Anders Kronström; Anders Mattson; Eva Mõller
- Web page: https://patentgrep.com/patent/US20120252847A1

## CPC

- C07D 401/12: linked by a chain containing hetero atoms as chain links
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 17/06: Antipsoriatics
- A61P 31/04: Antibacterial agents
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to a novel form of the (−)-enantiomer of 5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)-methyl]sulfinyl]-1H-benzimidazole, i.e. S-omeprazole. More specifically, it relates to a novel form of the magnesium salt of the S-enantiomer of omeprazole trihydrate. The present invention also relates to processes for preparing such a form of the magnesium salt of S-omeprazole and pharmaceutical compositions containing it. Furthermore, the present invention also relates to new intermediates used in the process.

## Claims

### Claim at position 1

1-16. (canceled)

### Claim 17

A method of treating Helicobacter infections comprising the administration of an effective amount of the magnesium salt of S-omeprazole trihydrate and an antibacterial compound to a patient in need thereof.

### Claim 18 (depends on 17)

The method according to claim 17, wherein the magnesium salt of S-omeprazole trihydrate is represented by FIG. 1.

### Claim 19 (depends on 17)

The method according to claim 17, wherein the magnesium salt of S-omeprazole trihydrate is characterized by the following peaks in its X-ray diffractogram:
d-value/Å
Relative Intensity
2.67
m
2.79
m
3.27
m
3.52
s
3.82
s
3.96
vs
4.14
m
5.2
m
5.6
m
6.7
vs
6.9
s
8.3
w
16.6
vs

### Claim 20 (depends on 17)

The method according to claim 17, wherein the magnesium salt of S-omeprazole trihydrate is in a highly crystalline form.

### Claim 21 (depends on 17)

The method according to claim 17, wherein the magnesium salt of S-omeprazole trihydrate is in a stable form.

### Claim 22 (depends on 17)

The method according to claim 17, wherein the magnesium salt of S-omeprazole trihydrate is suitable for oral administration.

### Claim 23 (depends on 22)

The method according to claim 22, wherein the antibacterial compound is suitable for oral administration.

### Claim 24 (depends on 22)

The method according to claim 22, wherein the antibacterial compound is suitable for parenteral administration.

### Claim 25 (depends on 17)

The method according to claim 17, wherein the magnesium salt of S-omeprazole trihydrate is suitable for parenteral administration.

### Claim 26 (depends on 25)

The method according to claim 25 wherein the antibacterial compound is suitable for oral administration.

### Claim 27 (depends on 25)

The method according to claim 25, wherein the antibacterial compound is suitable for parenteral administration.

### Claim 28 (depends on 17)

The method according to claim 17, wherein the antibacterial compound is suitable for oral administration.

### Claim 29 (depends on 17)

The method according to claim 17, wherein the antibacterial compound is suitable for parenteral administration.

### Claim 30 (depends on 17)

The method according to claim 17, wherein the total daily dose of the magnesium salt of S-omeprazole trihydrate is from 10 mg to 80 mg.
